RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

With winter here, South Africa faces a rise in flu cases. This article explores the influenza virus, its symptoms, and effective prevention strategies, including vaccination and home remedies.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

When the seasonal flu strikes, most people expect the familiar lineup of fever, aches and congestion. But for many patients, dizziness emerges as an ...

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...